AVCT — Avacta Share News
0.000.00%
Last trade - 00:00- £318.31m
- £317.90m
- £0.11m
Brief: Avacta Announces Equity Fundraise Of £3.25 Mln
Equity fundraise of £3.25 million
Q2 2025 Business Update
Brief: Avacta Group Announces New Partial Response In FAP-Dox Phase 1b Trial
Posting of Annual Report and Revised Notice of AGM
Brief: Avacta Therapeutics Says FAP-Dox Initial Data In Salivary Gland Cancer Expected Late 2025
Preliminary Full Year 2024 Results
Board appointments
Update on timing of preliminary results
Notice of Results
Investor Webinar
Block Listing Application to AIM
Board change
Issue of Equity and Total Voting Rights
Brief: Avacta Group Says Ava6103 Phase 1 Trial To Begin Q1 2026
Avacta Quarterly Update
Brief: Avacta Therapeutics' AVA6000 Phase 1a Dose Escalation Shows Early Efficacy
UK's Avacta shines on sale of pathology solutions unit
Brief: Avacta Group To Sell Launch Diagnostics For 12.9 Million Pounds